CELL INTELLIGENCE · 肿瘤细胞治疗研究

双特异性 CAR-T 治疗髓外骨髓瘤：一首小圆舞曲

Bispecific CAR T for extramedullary myeloma: a minute waltz.

抗 BCMA/GPRC5D CAR-T 细胞用于伴骨外髓外病变的复发/难治性多发性骨髓瘤患者

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

双特异性 ANXA2/CD147 CAR-T 细胞疗法治疗骨肉瘤

Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma.

在体外 TIL 扩增过程中，CD40 和 41BB 通路的双重刺激增强了 CD8+ T 细胞的扩增

Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.

使用一种新型双特异性分子同时刺激 CD40 和 41BB 通路，可在质量和数量上增强 TIL 产品。这些发现支持将肿瘤浸润 B 细胞和 T 细胞双靶向作为一种有前景的策略，以优化 I 期试验中过继细胞治疗的 TIL 生产。

携带 BLM 突变的 DLBCL 患者在接受 CD19/CD22 双特异性 CAR-T 细胞治疗后发生继发性外周 T 细胞淋巴瘤

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

双特异性 CAR-T 和 CAR-NK 细胞在双重免疫治疗中的机遇与挑战

Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges.

增强 PD-L1 靶向提升 FOLR1- CAR NK92 细胞对卵巢癌的杀伤活性

Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer.

CAR-T 细胞治疗在肿瘤免疫治疗中的应用——生物学、临床成功与新兴挑战：综述

CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.

复发/难治性 B 细胞非霍奇金淋巴瘤中 CD19/20 CAR-T 疗法的临床结局与空间转录组图谱

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.